Philippe Daigle
Philippe Daigle is a biochemist, having received his B.Sc degree in 1999 from Université Laval, in Canada. In 2002, he completed his master’s degree in Organic chemistry specializing in analytical methods for the development of agrochemical compounds.
He then worked in sales and marketing in technical positions related to science applications. Philippe joined Lucas Meyer Cosmetics in 2017 as Product Manager for Southern Cross Botanicals and Borēaline® where he focuses on the development of sustainable, natural and upcycled active ingredients for the cosmetic industry.
Since the beginning of his career, Philippe has constantly contributed to technical and scientific publications.
Sophia Bull
Sophia Bull joined Lucas Meyer Cosmetics as the Technical Marketing Manager for North America in 2019. In this role she supports customers and delivers regionalized promotions and product launches. She is based at the IFF headquarters in New York City.
After several years working in the pharmaceutical industry, Sophia began her career in the personal care industry working in regulatory for Croda, building on her technical background. Roles in marketing and sales followed at Croda and then at Botaneco, a Canadian natural ingredient startup.
Sophia obtained her master’s degree in chemistry from the University of Leeds, UK.
Tania Small
Tania Small, MD is Global Medical Affairs Therapeutic Area Head of Oncology at GSK and Chair of the diversity, equity, and inclusion R&D Council. She has built and leads an organization of approximately 500 professionals focused on patient-driven science, breaking down the barriers to access and driving impactful and innovative solutions to improve the outcome of individuals with cancers. Dr. Small was trained in Hematology/Oncology and bone marrow transplant at Columbia University, New York Presbyterian where she also completed a genetic research fellowship. She subsequently continued her focused on both hematology and stem cell transplant. She has done research in oncology, hematology, gene therapy and stem cell transplantation, and received grants from the U.S. National Institutes of Health (NIH) for her translational research in gene therapy and regenerative medicine. In previous roles with Novartis Oncology and Ipsen, Dr. Small successfully led the launch programs of multiple oncology therapies while overseeing both clinical development programs as well as medical affairs programs. She has also led many patient-centered and diversity initiatives in previous roles, working closely with the U.S. FDA, Congress and the American Society of Clinical Oncology (ASCO) to improve the diversity enrollment into oncology clinical trials and elderly programs. She is passionate about creating a world class oncology program that will successfully deliver the transformational medicines needed to revolutionize the experience and outcomes of patients.
Nathanial DeNicola
Maximilian Groth
Maximilian Groth is the CEO and co-founder of Decentriq, an enterprise SaaS platform providing data clean rooms powered by confidential computing – allowing users to leverage data previously not possible. Along with his co-founder Stefan Deml and the Decentriq team, he has enabled data ecosystems for a range of global enterprises.
Before founding Decentriq, Max worked at Teralytics in the Business Development, a company focusing on the monetization of telecommunication data.
Max received his Master’s in Arts from the University of Sant Gallen, , specializing in Accounting and Finance.
